Drug Trial Radar · NCT04929483
Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)
Last checked: Nov 19, 2026Latest source record: Jan 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
222
Actual
Start
Jun 4, 2021
Primary completion
Feb 14, 2023
Study completion Oct 8, 2024
Sponsor
- Lead sponsor
- 89bio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 18, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 21 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled study that will evaluate the safety, efficacy, tolerability of BIO89-100 in patients with biopsy-confirmed fibrosis stages F2-F3 NASH.
Conditions
- NASH - Nonalcoholic Steatohepatitis
Interventions
BIO89-100Drug
Subcutaneous injection
PlaceboDrug
Subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Main Study: Number of Participants With Histological Resolution of Nonalcoholic Steatohepatitis (NASH) Without Worsening of FibrosisTime frame: Week 24
- Main Study: Number of Participants Who Achieved Improvement of Fibrosis ≥1 Stage Without Worsening of NASHTime frame: Week 24
Locations
89 sites in 2 countries. Site status is shown where the registry gives one.
89bio Clinical Study Site
Birmingham, Alabama
89bio Clinical Study Site
Birmingham, Alabama
89bio Clinical Study Site
Dothan, Alabama
89bio Clinical Study Site
Guntersville, Alabama
89bio Clinical Study Site
Madison, Alabama
89bio Clinical Study Site
Chandler, Arizona
89bio Clinical Study Site
Glendale, Arizona
89bio Clinical Study Site
Peoria, Arizona
89bio Clinical Study Site
Tucson, Arizona
89bio Clinical Study Site
Tucson, Arizona
89bio Clinical Study Site
Tucson, Arizona
89bio Clinical Study Site
Little Rock, Arkansas
89bio Clinical Study Site
Little Rock, Arkansas
89bio Clinical Study Site
Chula Vista, California
89bio Clinical Study Site
Huntington Park, California
89bio Clinical Study Site
Long Beach, California
89bio Clinical Study Site
Orange, California
89bio Clinical Study Site
Panorama City, California
89bio Clinical Study Site
Rialto, California
89bio Clinical Study Site
Santa Ana, California
89bio Clinical Study Site
Englewood, Colorado
89bio Clinical Study Site
Boynton Beach, Florida
89bio Clinical Study Site
Bradenton, Florida
89bio Clinical Study Site
Fort Myers, Florida
89bio Clinical Study Site
Lakeland, Florida
89bio Clinical Study Site
Maitland, Florida
89bio Clinical Study Site
Miami, Florida
89bio Clinical Study Site
Miami, Florida
89bio Clinical Study Site
Miami, Florida
89bio Clinical Study Site
Miami Lakes, Florida
89bio Clinical Study Site
Ocala, Florida
89bio Clinical Study Site
Palmetto Bay, Florida
89bio Clinical Study Site
Pinellas Park, Florida
89bio Clinical Study Site
Port Orange, Florida
89bio Clinical Study Site
Sarasota, Florida
89bio Clinical Study Site
Viera, Florida
89bio Clinical Study Site
Athens, Georgia
89bio Clinical Study Site
Sandy Springs, Georgia
89bio Clinical Study Site
New Albany, Indiana
89bio Clinical Study Site
South Bend, Indiana
Showing 40 of 89 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.